Diabetes Update | US Pharmacist

November 2021

Higher Semaglutide Doses Even Better for Weight Loss and Diabetes Control?
A recent study in Lancet Diabetes & Endocrinology reports that higher doses of the glucagon-like peptide 1 agonist semaglutide could offer another treatment option and appear to result in even better outcomes for both weight loss and diabetes. This dosing alternative is currently under FDA review, but the authors are hopeful given the results they obtained using the higher doses. Read more.

SARS-CoV-2-Infected Adipose Tissue Appears to Heighten Diabetes Risk
The COVID-19 infection is well known for its association with serious risks, severe disease, and death. For many, an emerging trend of hyperglycemia triggered by the disruption of essential metabolic signals appears to be another risk. Find out what researchers from Weill Cornell Medicine and New York-Presbyterian are reporting in their study published in September 2021 in Cell Metabolism.

Avoiding Diabetic Intervention at Discharge Might Be Beneficial
The practice of optimizing medications when older adults are discharged from the hospital often includes increasing the dosage of diabetic medications to compensate for hyperglycemic excursions that may result from other medical conditions. Research published online in October 2021 in JAMA Network Open warns prescribers to avoid diabetic-regimen intensification in cases such as this to avoid severe hypoglycemic events post discharge. Read more.

Connect With U.S. Pharmacist